Life Sciences and Health Care companies are undergoing a period of intense transformation. Regulatory pressures are increasing, and new medical advances are occurring daily. Patent rule changes require careful management of your IP portfolio, and increased potential liability relating to your products and services requires you to be ever vigilant. Government and regulatory scrutiny is at an all-time high and commercial and government payors are demanding more effective cost controls. 

To meet these challenges and changes, you need a law firm that understands your issues and your business, and can effectively represent your interests anywhere in the world. At Dentons Rodyk, our dedicated team provides you with a wide array of services across the spectrum of health-related companies, combining deep industry knowledge and extensive legal experience. 

With offices in 79 locations in 52 countries across four continents, and with more than 100 lawyers, consultants and policy professionals who have spent their professional careers counselling life sciences and health care organizations, we are always ready to assist you around the corner, or around the globe. 

In addition to lawyers’ seamless collaboration worldwide, we work closely with research institutes, leaders in scientific opinion, pharma-economic and medical experts and management advisers to provide the well-rounded, commercially focused service you need. 

Insights

Founders’ Conflict – Pre-empting Disputes when all is well

January 6, 2023

Singapore: Disputes amongst founders can happen anytime and for various reasons – not just when a company’s business is struggling but also when the entity is growing and more investors are investing with excitement. Something just goes amiss and there arises disagreements between founders. One then wonders what could have been done to pre-empt such issues? Or what can be done to address any issue that has arose? This article shares some suggestions that may help founders in managing misalignments whilst continuing their start-up’s journey in becoming the next unicorn.

Fund-raising document landscape in USA, Germany and Singapore

July 14, 2022

Singapore: The authors, from Dentons’ firms in Singapore and Germany, seek to provide a cross-border comparison of equity-related transactions documents often used in fund-raising transactions in USA, Germany and Singapore. The authors hope this can provide initial guidance to investors and founders of early-stage entities to better understand the legal documentation involved in an investment transaction in each of these countries.

India introduces amendments to biodiversity laws: What this means for business

January 7, 2022

Singapore: On December 16, 2021, India proposed amendments to the Biological Diversity Act of 2002 (the Act) by introducing the Biological Diversity (Amendment) Bill, 2021 (Bill). Among other things, the Act imposes an Access and Benefit Sharing (ABS) fee on companies that use biological resources in their operations. Companies – both Indian and MNCs, in the FMCG, cosmetics, life sciences, and agri-business sectors need to engage with the relevant Indian authorities to determine whether ABS fees apply to them and if so, what is the quantum of the fees. The amendments seek to make significant changes to Indian biodiversity laws and previous judicial pronouncements.

View all insights for Life Sciences and Health Care